PF 4217903

Drug Profile

PF 4217903

Alternative Names: PF-04217903; PF-4217903; PF-4217903-A

Latest Information Update: 04 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Amino alcohols; Antineoplastics; Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 28 Feb 2011 Discontinued - Phase-I for Cancer in USA (PO)
  • 27 Jul 2010 Suspended - Phase-I for Cancer in USA (PO)
  • 19 Mar 2010 Pfizer completes enrolment in its phase I trial for Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top